Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxelbased adjuvant chemotherapy in early-stage breast cancer patients

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 185-186

  Santini, D ^a   Galluzzo, S ^a   Vincenzi, B ^a   Zoccoli, A ^a   Ferraro, E ^a   Lippi, C ^b   Altomare, V ^a   Tonini, G ^a   Bertoldo, F ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ANTHRACYCLINE; DOCETAXEL; PARATHYROID HORMONE; VITAMIN D;

ADIPOSE TISSUE; ADJUVANT THERAPY; BODY FAT; BODY MASS; BONE METABOLISM; BREAST CANCER; CALCIUM TRANSPORT; CANCER ADJUVANT THERAPY; CANCER STAGING; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; VITAMIN BLOOD LEVEL; WEIGHT GAIN;

EID: 77949327958     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp497     Document Type: Letter

References (5)

1. Freedman DM, Looker AC, Chang SC et al. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007; 99: 1594-1602.
2. Wortsman J, Matsuoka LY, Chen TC et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-693.
3. Kailajarvi ME, Salminen EK, Paija OM et al. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res 2004; 24: 1271-1274.
4. Crew KD, Shane E, Cremers S et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009; 27: 2151-2156.
5. Goodwin PJ, Ennis M, Prithard KI et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-3763.